rs7519514 |
chr1 |
161739190 |
0.0000000306 |
A |
G |
White blood cell count |
ATF6 |
intron |
21738479
|
rs7519514 |
chr1 |
161739190 |
0.00000637 |
A |
G |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs905594 |
chr1 |
161741274 |
0.0000000532 |
T |
C |
White blood cell count |
ATF6 |
intron |
21738479
|
rs905594 |
chr1 |
161741274 |
0.0000352 |
T |
C |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs905594 |
chr1 |
161741274 |
0.00000381 |
T |
C |
Diabetes Mellitus |
ATF6 |
intron |
pha003059
|
rs1027700 |
chr1 |
161757036 |
0.000000115 |
A |
T |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs6698956 |
chr1 |
161758744 |
0.0004616 |
T |
C |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
ATF6 |
intron |
23233654
|
rs6698956 |
chr1 |
161758744 |
0.000462 |
T |
C |
Methotrexate clearance (acute lymphoblastic leukemia) |
ATF6 |
intron |
23233662
|
rs11576878 |
chr1 |
161775577 |
0.000000206 |
A |
G |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs2134697 |
chr1 |
161780979 |
0.0000102 |
G |
A |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs16849542 |
chr1 |
161786495 |
1.77e-25 |
A |
G |
Narcolepsy |
ATF6 |
intron |
19629137
|
rs11581556 |
chr1 |
161793612 |
0.000000859 |
G |
A |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs10918029 |
chr1 |
161795896 |
0.0004025 |
G |
A |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
ATF6 |
intron |
23233654
|
rs10918029 |
chr1 |
161795896 |
0.000403 |
G |
A |
Methotrexate clearance (acute lymphoblastic leukemia) |
ATF6 |
intron |
23233662
|
rs12691498 |
chr1 |
161809706 |
0.000373 |
T |
A |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
ATF6 |
intron |
23233654
|
rs12691498 |
chr1 |
161809706 |
0.000373 |
T |
A |
Methotrexate clearance (acute lymphoblastic leukemia) |
ATF6 |
intron |
23233662
|
rs1006310 |
chr1 |
161811555 |
0.000000261 |
T |
C |
White blood cell count |
ATF6 |
intron |
21738479
|
rs1006310 |
chr1 |
161811555 |
0.000586 |
T |
C |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs3767635 |
chr1 |
161820904 |
0.000018 |
A |
G |
Urinary metabolites |
ATF6 |
intron |
21572414
|
rs931778 |
chr1 |
161823618 |
0.000000198 |
A |
G |
White blood cell count |
ATF6 |
intron |
21738479
|
rs931778 |
chr1 |
161823618 |
0.000873 |
A |
G |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs3767633 |
chr1 |
161826615 |
0.000008 |
T |
A |
IgG glycosylation |
ATF6 |
intron |
23382691
|
rs2340721 |
chr1 |
161849385 |
0.000000346 |
A |
C |
White blood cell count |
ATF6 |
intron |
21738479
|
rs2340721 |
chr1 |
161849385 |
0.000796 |
A |
C |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs10918137 |
chr1 |
161862555 |
0.000000336 |
G |
A |
White blood cell count |
ATF6 |
intron |
21738479
|
rs12124509 |
chr1 |
161867489 |
0.000000114 |
G |
A |
White blood cell count |
ATF6 |
intron |
21738479
|
rs2341475 |
chr1 |
161878608 |
0.0000885 |
A |
G |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs12079579 |
chr1 |
161880482 |
0.00056 |
G |
A |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
ATF6 |
intron |
23233654
|
rs12079579 |
chr1 |
161880482 |
0.00056 |
G |
A |
Methotrexate clearance (acute lymphoblastic leukemia) |
ATF6 |
intron |
23233662
|
rs4657121 |
chr1 |
161883083 |
0.00000079 |
G |
A |
Type 2 diabetes |
ATF6 |
intron |
22158537
|
rs4657121 |
chr1 |
161883083 |
0.0000449 |
G |
A |
Neuroblastoma |
ATF6 |
intron |
pha002895
|
rs7554023 |
chr1 |
161896364 |
0.00001 |
A |
G |
Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) |
ATF6 |
intron |
24023788
|
rs10918270 |
chr1 |
161915501 |
0.000008 |
G |
A |
Parkinson's disease (age of onset) |
ATF6 |
intron |
19772629
|
rs3795649 |
chr1 |
161931562 |
0.0000969 |
G |
A |
Heart Failure |
ATF6 |
UTR-3 |
pha002885
|